Nemaura Medical

Delisting of Securities of Latch, Inc.; Eloxx Pharmaceuticals, Inc.; Collective Audience, Inc. (f.k.a., ABRIC SPAC I); SeqLL Inc.; Nemaura Medical Inc.; LumiraDx Limited; Cemtrex Inc.; COMSovereign Holding Corp.; Global System Dynamics; Arrival; Nubia Bra

Retrieved on:

Wednesday, March 20, 2024

Latch, Therapy, Nemaura Medical, Cryptocurrency

Latch, Inc.’s securities were suspended on August 10, 2023, and have not traded on Nasdaq since that time.

Key Points:

Latch, Inc.’s securities were suspended on August 10, 2023, and have not traded on Nasdaq since that time.
Nasdaq also announced today that it will delist the warrants of Collective Audience, Inc.
Collective Audience, Inc.’s warrants were suspended on November 3, 2023, and have not traded on Nasdaq since that time.
Global System Dynamics’s securities were suspended on January 24, 2024, and have not traded on Nasdaq since that time.

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth

Retrieved on:

Tuesday, November 21, 2023

Nemaura Medical, NMRD, Security (finance)

Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans.

Key Points:

Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans.
Recognizing the challenges associated with equity sales, particularly in the small-cap landscape on the Nasdaq, Nemaura Medical has proactively pursued a funding strategy that minimizes dilution and, the Company believes, aligns with the best interests of its valued shareholders.
This $10 million credit facility, structured to be non-dilutive, empowers the Company to draw down a maximum of $1 million per month, providing a steady and controlled infusion of capital to support Nemaura Medical’s commercialization initiatives.
Dilution has long been a concern for public companies, and the Company believes that this credit facility not only addresses this concern but also positions Nemaura Medical for strategic growth.

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

Retrieved on:

Tuesday, November 14, 2023

Diet, Exercise, CGM, Obesity, Glucose, NHS, Conference, National Health Service, Quality of life, Pharmacotherapy, Sidoti, Weight loss, Education, Cryptocurrency, Pharmaceutical industry, Tirzepatide, Nemaura Medical

Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemented by pharmaceutical interventions using GLP-1 agonists such as Ozempic, Wegovy and Mounjaro. This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets.

Key Points:

This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets.
Nemaura's program leverages the power of its world-first daily wear non-invasive CGM technology, allowing individuals to gain insights into how their body deals with glucose.
In pilot studies with the UK's National Health Service (NHS), Nemaura's program has demonstrated encouraging outcomes.
The incorporation of GLP-1 agonists like Ozempic, Wegovy and Mounjaro adds a powerful layer of support for individuals seeking effective and sustainable weight loss.

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update

Retrieved on:

Monday, November 13, 2023

Food, NMRD, Research, KSA, TP, Marketing, Nemaura Medical, Prediabetes, Kingdom, Cryptocurrency

Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended September 30, 2023 and provided a business update.

Key Points:

Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended September 30, 2023 and provided a business update.
The Company continued to support its UK licensee with its endeavours to obtain reimbursement for the sensors in the UK.
Advanced development of the Company’s BEATdiabetes offering in readiness for a commercial launch in due course.
Research and development (“R&D”) expenses were $491,803 and $257,061 for the three months ended September 30, 2023 and 2022, respectively.

Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference

Retrieved on:

Monday, September 18, 2023

Growth, NMRD, Nemaura Medical, Medical device, A.I

Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present business updates and developments at the Maxim Group Emerging Growth in A.I., virtual conference.

Key Points:

Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present business updates and developments at the Maxim Group Emerging Growth in A.I., virtual conference.
The presentation will take place at 11am Eastern time on 27 September 2023.
Register for the conference here: www.m-vest.com

Weight-loss Programs Level Up With Smart Wearable Devices

Retrieved on:

Friday, September 15, 2023

NEW YORK, Sept. 15, 2023 /PRNewswire/ -- The wearable technology market has evolved in recent years into a major tech segment, in large part thanks to consumer market growth which is driven by sales of smartwatches. Major companies like Apple and Samsung are heavily involved in the innovation of wearable devices, which are now capable of performing a wide range of features including cellular connectivity, health monitoring, contactless payment and more. Due to the advanced health monitoring features found in the devices, the wearable technology market is now playing an important role in the medical sector as well. In recent years, the devices have allowed healthcare providers to remotely monitor a patient's various physiological parameters. The most commonly measured data include vital signs such as heart rate, blood pressure, number of calories burned during a day, sleep quality and oxygen level in the blood. Nemaura Medical Inc. (NASDAQ: NMRD), Planet Fitness, Inc. (NYSE: PLNT), WW International, Inc. (NASDAQ: WW), Garmin Ltd. (NYSE: GRMN), iRhythm Technologies, Inc. (NASDAQ: IRTC)

Key Points:

Due to the advanced health monitoring features found in the devices, the wearable technology market is now playing an important role in the medical sector as well.
In recent years, the devices have allowed healthcare providers to remotely monitor a patient's various physiological parameters.
Nemaura Medical Inc. (NASDAQ: NMRD) announced breaking news earlier this week regarding, "interim results from its metabolic health program.
The high medical needs designation in Japan is granted to innovative devices recognized as having high medical utility for significant diseases.

Weight-loss Programs Level Up With Smart Wearable Devices

Retrieved on:

Friday, September 15, 2023

NEW YORK, Sept. 15, 2023 /PRNewswire/ -- The wearable technology market has evolved in recent years into a major tech segment, in large part thanks to consumer market growth which is driven by sales of smartwatches. Major companies like Apple and Samsung are heavily involved in the innovation of wearable devices, which are now capable of performing a wide range of features including cellular connectivity, health monitoring, contactless payment and more. Due to the advanced health monitoring features found in the devices, the wearable technology market is now playing an important role in the medical sector as well. In recent years, the devices have allowed healthcare providers to remotely monitor a patient's various physiological parameters. The most commonly measured data include vital signs such as heart rate, blood pressure, number of calories burned during a day, sleep quality and oxygen level in the blood. Nemaura Medical Inc. (NASDAQ: NMRD), Planet Fitness, Inc. (NYSE: PLNT), WW International, Inc. (NASDAQ: WW), Garmin Ltd. (NYSE: GRMN), iRhythm Technologies, Inc. (NASDAQ: IRTC)

Key Points:

Due to the advanced health monitoring features found in the devices, the wearable technology market is now playing an important role in the medical sector as well.
In recent years, the devices have allowed healthcare providers to remotely monitor a patient's various physiological parameters.
Nemaura Medical Inc. (NASDAQ: NMRD) announced breaking news earlier this week regarding, "interim results from its metabolic health program.
The high medical needs designation in Japan is granted to innovative devices recognized as having high medical utility for significant diseases.

Nemaura Medical Provides Update on Nasdaq Compliance Status and Process

Retrieved on:

Thursday, September 14, 2023

National Health Service, Calendar, Nemaura Medical, SFDA, Panel, Hearing, Staff, NMRD, UK, Food, Pharmaceutical industry

LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .

Key Points:

LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .
(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provided an update regarding the status of its compliance with Nasdaq continued listed standards and anticipated next steps to maintain its listing on The Nasdaq Capital Market.
The Company plans to timely request such hearing and is considering all options available to it to regain compliance and maintain its listing on The Nasdaq Capital Market.
Dr Faz Chowdhury, the Company’s Chief Executive Officer, commented, “We are hopeful that there will be a positive outcome from a hearing before the Panel.

Nemaura Medical Announces Participation at HLTH 2023, Las Vegas

Retrieved on:

Tuesday, September 12, 2023

CGM, Diabetes, Continuous glucose monitor, Prediabetes, Patient, Korea Disease Control and Prevention Agency, Architecture, Health, Nemaura Medical, NMRD, Dietary supplement, Medical device

LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .

Key Points:

LOUGHBOROUGH, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc .
(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting diabetes management and personalized lifestyle coaching programs, today announced it will be participating at the HLTH 2023 conference, in Las Vegas, in October.
To support third parties, the Company has made modifications to its architecture to enable sensor integration with other digital programs.
This strategy is expected to allow Nemaura to scale its commercialisation programs rapidly and cost-efficiently.

Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results

Retrieved on:

Monday, September 11, 2023

CGM, CE, Male, Type 2 diabetes, Diabetes, Nemaura Medical, Saudi Food and Drug Authority, SFDA, Person, MARD, Patient, Ageing, NMRD, Skin, Female, Calibration

The Company has previously received CE approval in Europe, and SFDA (Saudi Food and Drug Authority) approval for its sugarBEAT® glucose sensor for a wear period of 14 hours.

Key Points:

The Company has previously received CE approval in Europe, and SFDA (Saudi Food and Drug Authority) approval for its sugarBEAT® glucose sensor for a wear period of 14 hours.
This study was designed to evaluate several factors, including the possibility of increasing the wear period to up to 24 hours, evaluating the possibility of auto-calibration, and different methods of application of the device to the skin.
The Company reports interim data from a first cohort comprising 25 patients, on a single day sensor wear.
The results indicate that a 24-hour sensor wear period using a single sensor is possible, which is expected to allow users to monitor their glucose fluctuations overnight.